G M Iverson

Summary

Affiliation: La Jolla Pharmaceutical Company
Country: USA

Publications

  1. ncbi The orientation of beta2GPI on the plate is important for the binding of anti-beta2GPI autoantibodies by ELISA
    G Michael Iverson
    La Jolla Pharmaceutical Co, 6455 Nancy Ridge Drive, San Diego, CA 92121, USA
    J Autoimmun 18:289-97. 2002
  2. ncbi Detection and characterization of B cell epitopes on beta2-glycoprotein I
    Keith A Cockerill
    La Jolla Pharmaceutical Company, San Diego, CA 92121, USA
    Clin Immunol 112:129-35. 2004
  3. pmc Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI
    G M Iverson
    La Jolla Pharmaceutical Company, San Diego, CA 92121, USA
    Proc Natl Acad Sci U S A 95:15542-6. 1998
  4. ncbi Advances in understanding what we measure when detecting anticardiolipin autoantibodies
    G Michael Iverson
    La Jolla Pharmaceutical Company, 6455 Nancy Ridge Drive, San Diego, CA 92121, USA
    Clin Chim Acta 343:37-44. 2004
  5. ncbi Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies
    G Michael Iverson
    La Jolla Pharmaceutical Co, San Diego, CA 92121, USA
    J Immunol 169:7097-103. 2002
  6. ncbi Synthesis of LJP 993, a multivalent conjugate of the N-terminal domain of beta2GPI and suppression of an anti-beta2GPI immune response
    D S Jones
    La Jolla Pharmaceutical Company, 6455 Nancy Ridge Drive, San Diego, California 92121, USA
    Bioconjug Chem 12:1012-20. 2001
  7. ncbi Multivalent thioether-peptide conjugates: B cell tolerance of an anti-peptide immune response
    D S Jones
    La Jolla Pharmaceutical Company, 6455 Nancy Ridge Drive, San Diego, California 92121, USA
    Bioconjug Chem 10:480-8. 1999
  8. ncbi Pre-treatment affinity for LJP 394 influences pharmacodynamic response in lupus patients
    P A McNeeley
    La Jolla Pharmaceutical Company, San Diego, California 92121, USA
    Lupus 10:526-32. 2001
  9. ncbi Anti-beta(2)-glycoprotein I antibody-mediated inhibition of activated protein C requires binding of beta(2)-glycoprotein I to phospholipids
    Tomonori Izumi
    Division of Hematology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Thromb Haemost 88:620-6. 2002
  10. pmc Beta 2-Glycoprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: loss of inhibition by clipped beta 2-glycoprotein I
    Tong Shi
    Department of Medicine, St George Hospital, University of New South Wales, Kogarah 2217, Australia
    Proc Natl Acad Sci U S A 101:3939-44. 2004

Collaborators

Detail Information

Publications15

  1. ncbi The orientation of beta2GPI on the plate is important for the binding of anti-beta2GPI autoantibodies by ELISA
    G Michael Iverson
    La Jolla Pharmaceutical Co, 6455 Nancy Ridge Drive, San Diego, CA 92121, USA
    J Autoimmun 18:289-97. 2002
    ..These results strongly suggest that the orientation of beta2GPI on the microplate, and not necessarily the lateral density, plays the predominant role in the binding of autoantibodies...
  2. ncbi Detection and characterization of B cell epitopes on beta2-glycoprotein I
    Keith A Cockerill
    La Jolla Pharmaceutical Company, San Diego, CA 92121, USA
    Clin Immunol 112:129-35. 2004
    ..Finally, we review evidence identifying a dominant B cell epitope that is partially defined by residues Gly40 and Arg43 on the amino terminal domain of beta2GPI...
  3. pmc Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI
    G M Iverson
    La Jolla Pharmaceutical Company, San Diego, CA 92121, USA
    Proc Natl Acad Sci U S A 95:15542-6. 1998
    ..The domain-deleted mutants that contained domain 1 inhibited all aCL in a similar but not identical pattern, suggesting that these aCL recognize a similar, but distinguishable, epitope(s) present on domain 1...
  4. ncbi Advances in understanding what we measure when detecting anticardiolipin autoantibodies
    G Michael Iverson
    La Jolla Pharmaceutical Company, 6455 Nancy Ridge Drive, San Diego, CA 92121, USA
    Clin Chim Acta 343:37-44. 2004
    ..We present further evidence supporting our hypothesis that most of these autoantibodies recognize epitope(s) located on domain 1 (DI) of beta2-glycoprotein 1 (beta2GPI)...
  5. ncbi Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies
    G Michael Iverson
    La Jolla Pharmaceutical Co, San Diego, CA 92121, USA
    J Immunol 169:7097-103. 2002
    ..This study confirms that anti-beta(2)GPI autoantibodies bind to domain I, and that the charged surface patch defined by residues 40-43 contributes to a dominant target epitope...
  6. ncbi Synthesis of LJP 993, a multivalent conjugate of the N-terminal domain of beta2GPI and suppression of an anti-beta2GPI immune response
    D S Jones
    La Jolla Pharmaceutical Company, 6455 Nancy Ridge Drive, San Diego, California 92121, USA
    Bioconjug Chem 12:1012-20. 2001
    ..Host mice receiving cells that were treated with LJP 993 produced significantly lower amounts of anti-domain 1 antibodies than controls which received untreated cells, indicative of B cell tolerance...
  7. ncbi Multivalent thioether-peptide conjugates: B cell tolerance of an anti-peptide immune response
    D S Jones
    La Jolla Pharmaceutical Company, 6455 Nancy Ridge Drive, San Diego, California 92121, USA
    Bioconjug Chem 10:480-8. 1999
    ..Three of the four conjugates suppressed the formation of anti-peptide antibody. The stabilities of the conjugates in mouse serum were measured, and the relative stabilities did not correlate with ability to suppress antibody formation...
  8. ncbi Pre-treatment affinity for LJP 394 influences pharmacodynamic response in lupus patients
    P A McNeeley
    La Jolla Pharmaceutical Company, San Diego, California 92121, USA
    Lupus 10:526-32. 2001
    ..These results suggest it may be possible to use an affinity assay to define prospectively patients that are most likely to exhibit the desired pharmacodynamic response to LJP 394...
  9. ncbi Anti-beta(2)-glycoprotein I antibody-mediated inhibition of activated protein C requires binding of beta(2)-glycoprotein I to phospholipids
    Tomonori Izumi
    Division of Hematology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Thromb Haemost 88:620-6. 2002
    ..This study confirms that anti-beta(2)GPI antibodies from APS patients inhibit APC activity, and demonstrates the requirement of phospholipid binding of beta(2)GPI for expression of the inhibitory activity of these antibodies...
  10. pmc Beta 2-Glycoprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: loss of inhibition by clipped beta 2-glycoprotein I
    Tong Shi
    Department of Medicine, St George Hospital, University of New South Wales, Kogarah 2217, Australia
    Proc Natl Acad Sci U S A 101:3939-44. 2004
    ..Plasmin cleavage of beta(2)GPI provides a negative feedback that counteracts its inhibition of FXI activation...
  11. ncbi Heparin inhibits the binding of beta 2-glycoprotein I to phospholipids and promotes the plasmin-mediated inactivation of this blood protein. Elucidation of the consequences of the two biological events in patients with the anti-phospholipid syndrome
    Jan Guerin
    Department of Immunology, Division of Medicine, University of New South Wales, St George Hospital, Sydney, New South Wales 2217, Australia
    J Biol Chem 277:2644-9. 2002
    ..This, in turn, decreases the prothrombotic activity of the endogenous circulating anti-beta2-GPI antibodies in the patients. Thus, heparin exerts its beneficial effects in APS patients by at least two distinct mechanisms...
  12. ncbi Therapeutic potential of toleragens in the management of antiphospholipid syndrome
    Keith A Cockerill
    La Jolla Pharmaceutical Company, San Diego, California, USA
    BioDrugs 18:297-305. 2004
    ..Preliminary results from a phase I/II clinical trial with LJP 1082, a B-cell toleragen, indicate the drug was well tolerated and may warrant further development for reduction of thrombotic events in patients with APS...
  13. ncbi Domain V of beta2-glycoprotein I binds factor XI/XIa and is cleaved at Lys317-Thr318
    Tong Shi
    Department of Medicine, Department of Immunology, Allergy and Infectious Diseases, St George Hospital, University of New South Wales, Sydney, New South Wales 2217, Australia
    J Biol Chem 280:907-12. 2005
    ..We also demonstrate that FXIa proteolytically cleaves beta2GPI at Lys317-Thr318 in DV. Thus, FXIa cleavage of beta2GPI in vivo during thrombus formation may accelerate FXI activation by decreasing the inhibitory effect of beta2GPI...
  14. ncbi Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V
    Tong Shi
    St George Hospital, University of New South Wales, Sydney, New South Wales, Australia
    Arthritis Rheum 54:2558-67. 2006
    ..We undertook this study to investigate the possible contribution of the GPIb-IX-V receptor to platelet activation mediated by the anti-beta2GPI antibody-beta2GPI complex...
  15. ncbi Patients with atherosclerotic syndrome, negative in anti-cardiolipin assays, make IgA autoantibodies that preferentially target domain 4 of beta2-GPI
    G Michael Iverson
    INOVA Diagnostics, Inc, 9900 Old Grove Road, San Diego, CA 92131 1638, USA
    J Autoimmun 27:266-71. 2006
    ..These results clearly show that IgA anti-beta2-GPI autoantibodies from atherosclerotic patients are distinct from IgA autoantibodies found in APS samples...